亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

医学 易普利姆玛 无容量 临床终点 内科学 肿瘤科 中期分析 肺癌 临床研究阶段 实体瘤疗效评价标准 临床试验 癌症 化疗 外科 免疫疗法
作者
Luis G Paz-Ares,Tudor–Eliade Ciuleanu,Manuel Cobo,Michael Schenker,Bogdan A. Żurawski,Juliana Janoski De Menezes,Eduardo Richardet,Jaafar Bennouna,Enriqueta Felip,Óscar Juan,Aurelia Alexandru,Hiroshi Sakai,Alejo Lingua,Pamela Salman,Pierre-Jean Souquet,Pedro De Marchi,Claudio Marcelo Martin,Maurice Pérol,Arnaud Scherpereel,Shun Lü
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:22 (2): 198-211 被引量:1447
标识
DOI:10.1016/s1470-2045(20)30641-0
摘要

First-line nivolumab plus ipilimumab has shown improved overall survival in patients with advanced non-small-cell lung cancer (NSCLC). We aimed to investigate whether the addition of a limited course (two cycles) of chemotherapy to this combination would further enhance the clinical benefit.This randomised, open-label, phase 3 trial was done at 103 hospitals in 19 countries. Eligible patients were aged 18 years or older with treatment-naive, histologically confirmed stage IV or recurrent NSCLC, and an Eastern Cooperative Oncology Group performance status of 0-1. Patients were randomly assigned (1:1) by an interactive web response system via permuted blocks (block size of four) to nivolumab (360 mg intravenously every 3 weeks) plus ipilimumab (1 mg/kg intravenously every 6 weeks) combined with histology-based, platinum doublet chemotherapy (intravenously every 3 weeks for two cycles; experimental group), or chemotherapy alone (every 3 weeks for four cycles; control group). Randomisation was stratified by tumour histology, sex, and PD-L1 expression. The primary endpoint was overall survival in all randomly assigned patients. Safety was analysed in all treated patients. Results reported here are from a pre-planned interim analysis (when the study met its primary endpoint) and an exploratory longer-term follow-up analysis. This study is active but no longer recruiting patients, and is registered with ClinicalTrials.gov, number NCT03215706.Between Aug 24, 2017, and Jan 30, 2019, 1150 patients were enrolled and 719 (62·5%) randomly assigned to nivolumab plus ipilimumab with two cycles of chemotherapy (n=361 [50%]) or four cycles of chemotherapy alone (n=358 [50%]). At the pre-planned interim analysis (median follow-up 9·7 months [IQR 6·4-12·8]), overall survival in all randomly assigned patients was significantly longer in the experimental group than in the control group (median 14·1 months [95% CI 13·2-16·2] vs 10·7 months [9·5-12·4]; hazard ratio [HR] 0·69 [96·71% CI 0·55-0·87]; p=0·00065). With 3·5 months longer median follow-up (median 13·2 months [IQR 6·4-17·0]), median overall survival was 15·6 months (95% CI 13·9-20·0) in the experimental group versus 10·9 months (9·5-12·6) in the control group (HR 0·66 [95% CI 0·55-0·80]). The most common grade 3-4 treatment-related adverse events were neutropenia (in 24 [7%] patients in the experimental group vs 32 [9%] in the control group), anaemia (21 [6%] vs 50 [14%]), diarrhoea (14 [4%] vs two [1%]), increased lipase (22 [6%] vs three [1%]), and asthenia (tjree [1%] vs eight [2%]). Serious treatment-related adverse events of any grade occurred in 106 (30%) patients in the experimental group and 62 (18%) in the control group. Seven (2%) deaths in the experimental group (acute kidney failure, diarrhoea, hepatotoxicity, hepatitis, pneumonitis, sepsis with acute renal insufficiency, and thrombocytopenia; one patient each) and six (2%) deaths in the control group (anaemia, febrile neutropenia, pancytopenia, pulmonary sepsis, respiratory failure, and sepsis; one patient each) were treatment related.Nivolumab plus ipilimumab with two cycles of chemotherapy provided a significant improvement in overall survival versus chemotherapy alone and had a favourable risk-benefit profile. These data support this regimen as a new first-line treatment option for patients with advanced NSCLC.Bristol Myers Squibb.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
淡然的冰淇淋完成签到 ,获得积分10
7秒前
坦率的邑完成签到 ,获得积分10
15秒前
19秒前
冷酷的祥完成签到,获得积分10
19秒前
睡觉大王__完成签到,获得积分10
21秒前
科研小白发布了新的文献求助10
22秒前
obedVL完成签到,获得积分10
23秒前
风趣含双发布了新的文献求助10
31秒前
背后寒烟完成签到 ,获得积分10
34秒前
Yh完成签到,获得积分10
39秒前
从容棉花糖完成签到,获得积分10
40秒前
cloud完成签到 ,获得积分10
41秒前
Yh发布了新的文献求助10
42秒前
敬业乐群完成签到,获得积分10
46秒前
陈龙完成签到,获得积分10
51秒前
aa完成签到,获得积分10
55秒前
LSQ完成签到,获得积分10
1分钟前
1分钟前
foden完成签到,获得积分10
1分钟前
xinran完成签到,获得积分10
1分钟前
温暖的帆布鞋完成签到,获得积分10
1分钟前
yli130完成签到,获得积分10
1分钟前
1分钟前
1分钟前
Sarahminn发布了新的文献求助10
1分钟前
1分钟前
俏皮的灵发布了新的文献求助10
1分钟前
机灵的沂完成签到,获得积分10
1分钟前
奔跑的应助被虚心的灵寒采纳,获得10
1分钟前
奔跑的应助被虚心的灵寒采纳,获得10
1分钟前
欢呼的兰完成签到,获得积分10
1分钟前
华仔的应助被lmn采纳,获得10
1分钟前
酒酿是也完成签到 ,获得积分10
1分钟前
满意的楷瑞完成签到,获得积分10
1分钟前
顺利的水瑶完成签到 ,获得积分10
1分钟前
1分钟前
我是老大的应助被科研通管家采纳,获得10
1分钟前
彭于晏的应助被科研通管家采纳,获得10
1分钟前
1分钟前
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8172954
求助须知:如何正确求助?哪些是违规求助? 9565447
关于积分的说明 21780029
捐赠科研通 7764817
什么是DOI,文献DOI怎么找? 3431496
关于科研通互助平台的介绍 2555519
邀请新用户注册赠送积分活动 2476571